As we await the Leiden data to hopefully cement MPL as a solid player as an Oral Treatment of Cov19 symptoms thought this post might be able to refresh the Market on what PAA has already achieved.
April 17th 2020PharmAust and Walter and Eliza Hall Institute to Evaluate Monepantel on COVID-19 Infection Modelhttps://stocknessmonster.com/announcements/paa.asx-6A975502/
18th June 2020
Confirmation of Preliminary COVID-19 Results Following
Monepantel Treatment In Vitro
• Monepantel and monepantel sulfone treatment both reduce SARS-CoV-2 (COVID-19)
cell-to-cell infectivity in cell culture in a repeat preliminary experimental evaluation
• Repeat preliminary experiment data demonstrate suppression of virus infectivity by
approximately 95% in cell culture by each drug
• Preparations for Phase 1 trialhttps://stocknessmonster.com/announcements/paa.asx-6A975502/
25th of August
Inhibition of SARS-CoV-2 by Monepantel in Preliminary Studies of Human Respiratory Calu-3 Cells In Vitro
• Monepantel and monepantel sulfone treatment both inhibit SARS-CoV-2 (COVID-19) in
preliminary work on cultured human lung adenocarcinoma epithelial cells (Calu-3 cells).
• Data demonstrate inhibition of virus by approximately 90 - 95% in Calu-3 cells by each drug.
• Monepantel and monepantel sulfone in preliminary work have now been demonstrated to
reduce SARS-CoV-2 infectivity in two independent cell lines: one non-human primate kidney
(VERO) and one human lung (Calu-3).
• This work requires repetition and robust verificationhttps://stocknessmonster.com/announcements/paa.asx-6A992675/September 9th 2020Monepantel Anti-viral Activity Against SARS-CoV-2
Confirmed
• Further testing demonstrates Monepantel (MPL) and monepantel sulfone (MPLS)
reduce SARS-CoV-2, the causative agent of COVID-19.
• Experimental results to date include repeat studies in VERO cells by two independent
laboratories and evaluation of SARS-CoV-2 anti-viral activity in human Calu-3 cells.
• MPL and MPLS have reduced virus burden regardless of laboratory, cell type or timing
of treatment (prior or post-infection).
•
Preparations for a Phase 1 clinical trial in humans in progress.
https://stocknessmonster.com/announcements/paa.asx-6A995129/September 24th 2020PharmAust and Leiden University Evaluate Monepantel
Suitability for Ex-Vivo Human COVID-19 Testing
• PharmAust will provide monepantel and monepantel sulfone to Leiden University
Medical Center where their ability to inhibit SARS-CoV-2 infection will be evaluated with
the intention to analyse their effect in ex-vivo human SARS-CoV-2 infection models
• Study will be overseen by Dr Martijn van Hemert, Principal Investigator of Anti-viral Drug
Development
• Final data report expected in December
https://stocknessmonster.com/announcements/paa.asx-6A997384/
This was really the tale of the tape , Dilution 5 took infection of Covid 19 Virus from over 31762 parts per million down to 469 parts per million in 72 hours...... that was the headline data easily missed by the market as the company supplied graphic was ..... not as clear as this one supplied by a SH ,,
Now we eagerly await the final data from Leiden ,, The Phase I preparation announced in June and again in September 9th could do with an update.
There has been talk "whispers" that Dilution 5 may have residual active sulfones that continue to fight SARs and SARs-2 based virus days after dosing,, would seem Pharmaust have the knowledge now that MPL works on Covid in the dish and on Humanoid Lung Tissue and Leiden data may be able to confirm esophagus and nasal passage tissue dosed with MPL is also resistant to Cov , and may give a measure of immunity to infection entirely....
Physical Delivery of a Table/Pill for Oral dosing of MPL would be incredibly swift and easy compared to an intravenous vaccine where Clinicians have to be in harms way...
Looking forward to the News like many other Holders
(20min delay)